^
Association details:
| Biomarker: | KRAS wild-type + NRAS wild-type + MSI-H/dMMR |
|---|---|
| Cancer: | Colon Cancer |
| Drug: | Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Complete response of MSI-high metastatic colon cancer following treatment with regorafenib: A case report
Excerpt:
The patient underwent laparoscopic right hemicolectomy, and the pathology was T4aN2bM1, moderately differentiated adenocarcinoma with high microsatellite instability (MSI-H) and wild-type KRAS/NRAS….Thereafter, the patient received regorafenib as third-line therapy, starting with 160 mg for two cycles and reducing the dose thereafter, for a total of 17 cycles....This is the first report of refractory metastatic colon cancer with MSI-H showing a complete response to regorafenib.
DOI:
10.3892/mco.2021.2405
